Invivogen
Menu

Anti-hCTLA4-hIgG2

Anti-hCTLA4-hIgG2 Unit size Cat. code Docs Price
Human CTLA4 (ipilimumab) antibody - Human IgG2
Custom size
hctla4-mab2

January 28th, 2020.
This antibody has been removed from our catalog. However, you may contact us if you wish to order minimal quantities.

Monoclonal human IgG2 antibody against human CTLA-4

Anti-hCTLA4-hIgG2 features the constant region of the human IgG2 isotype and the variable region of ipilimumab. Ipilimumab is a fully human IgG1 monoclonal antibody that targets CTLA-4 (also known as CD152), a negative regulator of T cell activation.

By binding CTLA‑4, it inhibits negative signals that physiologically downregulate T cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes [1,2].

In addition, it induces antibody‑dependent cell-mediated cytotoxicity (ADCC) and TNF-α production [3]. Ipilimumab has been approved by the FDA for the treatment of unresectable or metastatic melanoma.

It is undergoing clinical trials for other types of cancers, including lung cancer [4].

Human IgG2 is the second most common antibody present in serum. This isotype is resistant to cleavage by proteolytic enzymes, due to a short hinge region.

Human IgG2 displays low complement-dependent cytotoxicity (CDC) and very low antibody-dependent cell-mediated cytotoxicity (ADCC).

Anti-hCTLA4-hIgG2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

 

References:

Grosso JF. & Jure-Kunkel MN., 2013. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13:5.
Maio M. et al., 2013. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 25:166-72.
Laurent S.. et al., 2013. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med. 11:108.
Tomasini P., 2012. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol. 4: 43–50.

Back to the top

Specifications

Specificity: Targets cells expressing human CTLA-4

Clonality: Monoclonal antibody

Isotype: Human IgG2, kappa

Source: CHO cells

Purity: Purified by affinity chromatography with protein G

Quality control:

  • Binding of Anti-hCTLA4-hIgG2 to human CTLA-4 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

  • 100 µg purified anti-hCTLA4-hIgG2 antibody, provided azide-free and lyophilized.

room temperature Product is shipped at room temperature.

store Store lyophilized antibody at -20°C.

stability Lyophilized product is stable for 1 year.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty